Polaryx Therapeutics, Inc. (PLYX)

Market Cap	169.49M
Revenue (ttm)	n/a
Net Income	-8.21M
EPS	-0.19
Shares Out	47.34M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	663,383
Open	2.720
Previous Close	2.740
Day's Range	2.640 - 3.788
52-Week Range	2.201 - 48.910
Beta	n/a
Analysts	Strong Buy
Price Target	10.00 (+179.33%)
Earnings Date	n/a

About PLYX

Polaryx Therapeutics, Inc., clinical-stage biotechnology company, develops small molecule and gene therapy treatments for lysosomal storage disorders. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 11
• Stock Exchange: NASDAQ
• Ticker Symbol: PLYX
• Website: https://polaryx.com

Analyst Summary

According to one analyst, the rating for PLYX stock is "Strong Buy" and the 12-month stock price target is $10.0.

Price Target

$10.0

(179.33% upside)

Analyst Consensus: Strong Buy